Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cediranib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 11/20 | 1.00 |
| ▸ | FLT4 known ✓ | P35916 | 5/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 4/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 1/20 | 1.00 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 4/20 | 1.00 |
| ▸ | TEK | Q02763 | 2/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 2/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | ERN1 | O75460 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | CHEK2 | O96017 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cediranib SCHEMBL29351458 | 1.00 | KDR (1.00) | KDRFLT4RETFLT1PDGFRB | |
| Cediranib SCHEMBL29368143 | 1.00 | KDR (1.00) | KDRFLT4RETFLT1PDGFRB | |
| Cediranib SCHEMBL29383181 | 1.00 | KDR (1.00) | KDRFLT4RETFLT1PDGFRB | |
| SCHEMBL1685423 | 0.99 | ABCB11 (1.00) | KDRFLT4RETFLT1PDGFRB | |
| SCHEMBL20077514 | 0.94 | KDR (0.89) | KDRFLT4RETFLT1PDGFRB | |
| Cediranib SCHEMBL4186434 | 0.94 | KDR (0.89) | KDRFLT4RETFLT1PDGFRB | |
| SCHEMBL3198096 | 0.94 | KDR (0.89) | KDRFLT4RETFLT1PDGFRB | |
| SCHEMBL13471998 | 0.94 | KDR (0.89) | KDRFLT4RETFLT1PDGFRB | |
| SCHEMBL1401668 | 0.94 | KDR (0.89) | KDRFLT4RETFLT1PDGFRB | |
| SCHEMBL1401641 | 0.93 | KDR (0.88) | KDRFLT4RETFLT1PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1926 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116059312-A | Integrin GPIIb/IIIa antagonists and their use in combination with anti-VEGF antibodies | 百奥泰生物制药股份有限公司 | 2023-05-05 | — | — | CN | claimed |
| US-20230091105-A1 | CHIMERIC FUSIONS BETWEEN C4-BINDING PROTEIN C-TERMINAL SEGMENT AND ANGIOPOIETIN-1 FIBRINOGEN-LIKE DOMAIN AS ANGIOPOIETIN MIMETICS AND TIE2 AGONISTS TO TREAT VASCULAR DISEASES | UNIV NORTHWESTERN (US) | 2023-03-23 | — | — | US | claimed |
| WO-2023001288-A1 | INTEGRIN GPIIB/IIIA ANTAGONIST AND APPLICATION THEREOF IN COMBINATION WITH ANTI-VEGF ANTIBODY | 百奥泰生物制药股份有限公司 | 2023-01-26 | — | — | WO | claimed |
| EP-4110796-A1 | CHIMERIC FUSIONS BETWEEN C4-BINDING PROTEIN C-TERMINAL SEGMENT AND ANGIOPOIETIN-1 FIBRINOGEN-LIKE DOMAIN AS ANGIOPOIETIN MIMETICS AND TIE2 AGONISTS TO TREAT VASCULAR DISEASES | Northwestern University (US) | 2023-01-04 | — | — | EP | claimed |
| CN-115485290-A | Chimeric fusions between C-terminal segments of C4-binding proteins and angiopoietin-1 fibrinogen-like domains as angiopoietin mimetics and Tie2 agonists for the treatment of vascular disease | 西北大学 | 2022-12-16 | — | — | CN | claimed |
| WO-2022245061-A1 | BENZAMIDE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER CONTAINING SAME AS ACTIVE INGREDIENT | 에이치케이이노엔 주식회사 | 2022-11-24 | — | — | WO | claimed |
| US-20210363231-A1 | OPTIMIZED ANTIBODY COMPOSITIONS FOR TREATMENT OF OCULAR DISORDERS | GENENTECH INC (US) | 2021-11-25 | — | — | US | claimed |
| US-20210115124-A1 | OPTIMIZED VARIANTS OF ANTI-VEGF ANTIBODIES | GENENTECH INC (US) | 2021-04-22 | — | — | US | claimed |
| US-20200222547-A1 | HYDROGEL CROSS-LINKED HYALURONIC ACID PRODRUG COMPOSITIONS AND METHODS | GENENTECH, INC. (US) | 2020-07-16 | — | — | US | claimed |
| CN-110891611-A | Hydrogel cross-linked hyaluronic acid prodrug compositions and methods | 基因泰克公司 | 2020-03-17 | — | — | CN | claimed |
| US-20060223815-A1 | Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use | ASTRAZENECA AB (SE) | 2006-10-05 | — | — | US | claimed |
| US-7074800-B1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2006-07-11 | — | — | US | claimed |
| US-20060135486-A1 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | EISAI CO., LTD. (JP) | 2006-06-22 | — | — | US | claimed |
| EP-1620104-A1 | THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE | Astrazeneca AB (SE) | 2006-02-01 | — | — | EP | claimed |
| EP-1553097-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATES THEREFORE | AstraZeneca AB (SE) | 2005-07-13 | — | — | EP | claimed |
| EP-1154774-B1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2005-06-22 | — | — | EP | claimed |
| WO-2004098604-A1 | THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE | ASTRAZENECA AB (SE) | 2004-11-18 | — | — | WO | claimed |
| US-20030144298-A1 | Using a combination of an angiogenisis inhibitor and a hypotensive agent for use in treating diseases associated with angiogenesis; an endothelial growth factor receptor tyrosine kinase inhibitor; antidiabetic, -arthritis agents | ASTRAZENECA AB (SE) | 2003-07-31 | — | — | US | claimed |
| EP-1272186-A1 | THERAPEUTIC COMBINATIONS OF ANTIHYPERTENSIVE AND ANTIANGIOGENIC AGENTS | AstraZeneca AB (SE) | 2003-01-08 | — | — | EP | claimed |
| WO-2001074360-A1 | THERAPEUTIC COMBINATIONS OF ANTIHYPERTENSIVE AND ANTIANGIOGENIC AGENTS | ASTRAZENECA AB (SE) | 2001-10-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135486-A1 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | FLT4, KDR, FLT1 | KDR 2/4885FLT4 1/4885FLT1 3/4885 |
| US-20210363231-A1 | OPTIMIZED ANTIBODY COMPOSITIONS FOR TREATMENT OF OCULAR DISORDERS | VEGFA, CD44, UACA | KDR 7/4885FLT4 6/4885FLT1 8/4885 |
| US-20060223815-A1 | Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use | SRC, TEK, FLT4 | KDR 5/4885FLT4 3/4885FLT1 4/4885 |
| US-20200222547-A1 | HYDROGEL CROSS-LINKED HYALURONIC ACID PRODRUG COMPOSITIONS AND METHODS | CD44, HCAR3, HPSE | KDR 1364/4885FLT4 1584/4885FLT1 1107/4885 |
| US-20210115124-A1 | OPTIMIZED VARIANTS OF ANTI-VEGF ANTIBODIES | VEGFA, FLT4, FLT1 | KDR 4/4885FLT4 2/4885FLT1 3/4885 |
| US-20030144298-A1 | Using a combination of an angiogenisis inhibitor and a hypotensive agent for use in treating diseases associated with angiogenesis; an endothelial growth factor receptor tyrosine kinase inhibitor; antidiabetic, -arthritis agents | TEK, TIE1, FLT1 | KDR 5/4885FLT4 4/4885FLT1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.